

Reference:

- Abreu, R.M. *et al.* (2013) ‘Hepatocellular carcinoma: The final moments of life’, *Journal of Cancer Therapy*, 04(02), pp. 377–383. doi:10.4236/jct.2013.42a045.
- Allaire, M., Rudler, M., & Thabut, D. (2021). *Portal hypertension and hepatocellular carcinoma: Des liaisons dangereuses.... Liver International*, 41(8), 1734–1743. doi:10.1111/liv.14977
- Alsaif, H.S., Hassan, A., Refai, O. *et al.* Concomitant hepatic tuberculosis and hepatocellular carcinoma: a case report and review of the literature. *BMC Surg* 21, 2 (2021). <https://doi.org/10.1186/s12893-020-01021-1>
- Amarapurkar, D.N., Patel, N.D. and Kamani, P.M. (2008) ‘Impact of diabetes mellitus on outcome of HCC’, *Annals of Hepatology*, 7(2), pp. 148–151. doi:10.1016/s1665-2681(19)31871-x.
- American Joint Committee on Cancer. Liver. Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, et al, eds. *AJCC Cancer Staging Manual*. 8th edition. New York: Springer; 2016.
- Aron-Wisnewsky J, Clement K, Pépin J-L. Nonalcoholic fatty liver disease and obstructive sleep apnea. *Metabolism* 2016; 65: 1124–1135
- Augustyn A, Peng L, Singal AG, Yopp AC. Surveillance for hepatocellular carcinoma secondary to cardiogenic cirrhosis in patients with congenital heart disease. *Clin Res Cardiol*. 2015 May;104(5):446-9. doi: 10.1007/s00392-015-0809-4. Epub 2015 Jan 21. PMID: 25875944; PMCID: PMC4768748.
- Balkwill, F., & Mantovani, A. (2001). Inflammation and cancer: back to Virchow?. *Lancet (London, England)*, 357(9255), 539–545. [https://doi.org/10.1016/S0140-6736\(00\)04046-0](https://doi.org/10.1016/S0140-6736(00)04046-0)
- Bhoori, S., Schiavo, M., Russo, A., & Mazzaferro, V. (2007). First-line treatment for hepatocellular carcinoma: resection or transplantation?. *Transplantation proceedings*, 39(7), 2271–2273. <https://doi.org/10.1016/j.transproceed.2007.06.015>
- Bialecki ES, Di Bisceglie AM. Diagnosis of hepatocellular carcinoma. *HPB (Oxford)*. 2005;7(1):26-34. doi: 10.1080/13651820410024049. PMID: 18333158; PMCID: PMC2023919.

- Borzio, M., Borzio, F., Macchi, R., Croce, A. M., Bruno, S., Ferrari, A., & Servida, E. (1994). The evaluation of fine-needle procedures for the diagnosis of focal liver lesions in cirrhosis. *Journal of hepatology*, 20(1), 117–121. [https://doi.org/10.1016/s0168-8278\(05\)80477-5](https://doi.org/10.1016/s0168-8278(05)80477-5)
- Calderon-Martinez, E., Landazuri-Navas, S., Vilchez, E., Cantu-Hernandez, R., Mosquera-Moscoso, J., Encalada, S., Al Lami, Z., Zevallos-Delgado, C., & Cinicola, J. (2023). Prognostic Scores and Survival Rates by Etiology of Hepatocellular Carcinoma: A Review. *Journal of clinical medicine research*, 15(4), 200–207. <https://doi.org/10.14740/jocmr4902>
- Cao, L., Wang, X., Yan, Y., Ning, Z., Ma, L., & Li, Y. (2023). Analysis of competing risks of cardiovascular death in patients with hepatocellular carcinoma: A population-based study. *Medicine*, 102(51), e36705. <https://doi.org/10.1097/MD.00000000000036705>
- Cebon Lipovec N, Beijers RJ, van den Borst B, et al. The prevalence of metabolic syndrome in chronic obstructive pulmonary disease: a systematic review. *COPD* 2016; 13: 399–406.
- Chen YJ, Shen CJ, Yu SH, Lin CL, Shih HM. Increased risk of hepatocellular carcinoma in patients with traumatic liver injury: Real-world data from a nationwide population-based study. *Medicine (Baltimore)*. 2022 Feb 11;101(6):e28837. doi: 10.1097/MD.00000000000028837. PMID: 35147128; PMCID: PMC8830875.
- Cleutjens F, Triest F, Wilke S, et al. New insights in chronic obstructive pulmonary disease and comorbidity. *Am J Respir Crit Care Med* 2015; 191: 1081–1082.
- Colli A, Fraquelli M, Casazza G, et al. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. *Am J Gastroenterol*. 2006;101(3):513–523. [PubMed] [Google Scholar]
- Collier J, Sherman M. Screening for hepatocellular carcinoma. *Hepatology*. 1998;27:273–278. [PubMed] [Google Scholar]
- Crissien, A. M., & Frenette, C. (2014). Current management of hepatocellular carcinoma. *Gastroenterology & hepatology*, 10(3), 153–161.

- Divella R, Mazzocca A, Daniele A, Sabbà C, Paradiso A. Obesity, Nonalcoholic Fatty Liver Disease and Adipocytokines Network in Promotion of Cancer. *Int J Biol Sci.* 2019 Jan 1;15(3):610-616. doi: 10.7150/ijbs.29599. PMID: 30745847; PMCID: PMC6367583.
- Divo M, Cote C, de Torres JP, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2012; 186: 155–161
- El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. *Gastroenterology.* 2012 May;142(6):1264-1273.e1. doi: 10.1053/j.gastro.2011.12.061. PMID: 22537432; PMCID: PMC3338949.
- El-Serag HB & Rudolph KL Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. *Gastroenterology* 132, 2557–2576 (2007).
- European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. *J Hepatol.* 2018;69(1):182-236.
- Fass, Ofer MD1; Jia, Nathan BS2; Ng, Jason MD1; Li, Clayton MD3; Sathe, Neha MD1. Hepatocellular Carcinoma Presenting as Right-Sided Heart Failure: 2189. *American Journal of Gastroenterology* 113():p S1248, October 2018.
- Forner, A., Llovet, J. M., & Bruix, J. (2012). Chemoembolization for intermediate HCC: is there proof of survival benefit?. *Journal of hepatology*, 56(4), 984–986. <https://doi.org/10.1016/j.jhep.2011.08.017>
- Gambarin-Gelwan M, Wolf DC, Shapiro R, Schwartz ME, Min AD. Sensitivity of commonly available screening tests in detecting hepatocellular carcinoma in hepatitis C virus cirrhosis. *Hepatology.* 2000;95:1535–1538.
- Hassanipour S, Vali M, Gaffari-Fam S, Nikbakht HA, Abdzadeh E, Joukar F, Pourshams A, Shafaghi A, Malakoutikhah M, Arab-Zozani M, Salehiniya H, Mansour-Ghanaei F. The survival rate of hepatocellular carcinoma in Asian countries: a systematic review and meta-analysis. *EXCLI J.* 2020 Jan 13;19:108-130. doi: 10.17179/excli2019-1842. PMID: 32038120; PMCID: PMC7003639.

- Hui L, Zatloukal K, Scheuch H, Stepniak E, Wagner EF. Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation. *J Clin Invest.* 2008 Dec;118(12):3943-53. doi: 10.1172/JCI37156. Epub 2008 Nov 6. PMID: 19033664; PMCID: PMC2579707.
- Jiao J, Friedman SL, Aloman C. Hepatic fibrosis. *Curr Opin Gastroenterol.* 2009 May;25(3):223-9. doi: 10.1097/mog.0b013e3283279668. PMID: 19396960; PMCID: PMC2883289.
- Jiao J, Zhang L. Liver Involvement by Perforated Peptic Ulcer: A Systematic Review. *J Clin Transl Pathol.* 2021;1(1):2-8. doi: 10.14218/JCTP.2021.00007.
- Krinsky, G. A., Lee, V. S., Theise, N. D., Weinreb, J. C., Rofsky, N. M., Diflo, T., & Teperman, L. W. (2001). Hepatocellular carcinoma and dysplastic nodules in patients with cirrhosis: prospective diagnosis with MR imaging and explantation correlation. *Radiology*, 219(2), 445–454. <https://doi.org/10.1148/radiology.219.2.r01ma40445>
- Lee, C. H., Hsieh, S. Y., Lin, J. L., Liu, M. S., & Yen, T. H. (2013). Hepatocellular carcinoma in patients with chronic kidney disease. *World journal of gastroenterology*, 19(16), 2466–2472. <https://doi.org/10.3748/wjg.v19.i16.2466>
- Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. *Semin Liver Dis.* 1999. 19 (3):329-38. [QxMD MEDLINE Link].
- Luca Cicalese, M. (2024) *Hepatocellular carcinoma (HCC), Practice Essentials, Anatomy, Pathophysiology*. Available at: <https://emedicine.medscape.com/article/197319-overview> (Accessed: 04 March 2024).
- Mancebo, A., González-Diéguez, M. L., Cadahía, V., Varela, M., Pérez, R., Navascués, C. A., Sotorriós, N. G., Martínez, M., Rodrigo, L., & Rodríguez, M. (2013). Annual incidence of hepatocellular carcinoma among patients with alcoholic cirrhosis and identification of risk groups. *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association*, 11(1), 95–101. <https://doi.org/10.1016/j.cgh.2012.09.007>
- Masuzaki R, Omata M. Screening program in high-risk populations. *Hepatocellular Carcinoma.* 2011:55–68.

- Mazzaferro, V., Bhoori, S., Sposito, C., Bongini, M., Langer, M., Miceli, R., & Mariani, L. (2011). Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. *Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society*, 17 Suppl 2, S44–S57. <https://doi.org/10.1002/lt.22365>
- Mazzaferro, V., Regalia, E., Doci, R., Andreola, S., Pulvirenti, A., Bozzetti, F., Montalto, F., Ammatuna, M., Morabito, A., & Gennari, L. (1996). Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. *The New England journal of medicine*, 334(11), 693–699. <https://doi.org/10.1056/NEJM199603143341104>
- Michielsen PP, Francque SM, van Dongen JL. Viral hepatitis and hepatocellular carcinoma. *World J Surg Oncol*. 2005 May 20;3:27. doi: 10.1186/1477-7819-3-27. PMID: 15907199; PMCID: PMC1166580.
- Morgan, T. R., Mandayam, S., & Jamal, M. M. (2004). Alcohol and hepatocellular carcinoma. *Gastroenterology*, 127(5 Suppl 1), S87–S96. <https://doi.org/10.1053/j.gastro.2004.09.020>
- Nakatsuka, T., & Tateishi, R. (2023). Development and prognosis of hepatocellular carcinoma in patients with diabetes. *Clinical and molecular hepatology*, 29(1), 51–64. <https://doi.org/10.3350/cmh.2022.0095>
- Nakayama H, Masuda H, Miyake H, Takayama T, Yokoyama E. Endoscopic Prediction of Hepatocellular Carcinoma by Evaluation of Bleeding Esophageal Varices. *DIG*. 2004;70(4):233-9.
- Nguyen, M. H., Garcia, R. T., Simpson, P. W., Wright, T. L., & Keeffe, E. B. (2002). Racial differences in effectiveness of alpha-fetoprotein for diagnosis of hepatocellular carcinoma in hepatitis C virus cirrhosis. *Hepatology (Baltimore, Md.)*, 36(2), 410–417. <https://doi.org/10.1053/jhep.2002.34744>
- Okuda, K., Ohtsuki, T., Obata, H., Tomimatsu, M., Okazaki, N., Hasegawa, H., Nakajima, Y., & Ohnishi, K. (1985). Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. *Cancer*, 56(4), 918–928.

[https://doi.org/10.1002/1097-0142\(19850815\)56:4<918::aid-cnrcr2820560437>3.0.co;2-e](https://doi.org/10.1002/1097-0142(19850815)56:4<918::aid-cnrcr2820560437>3.0.co;2-e)

- Oliver, J. H., 3rd, Baron, R. L., Federle, M. P., & Rockette, H. E., Jr (1996). Detecting hepatocellular carcinoma: value of unenhanced or arterial phase CT imaging or both used in conjunction with conventional portal venous phase contrast-enhanced CT imaging. *AJR. American journal of roentgenology*, 167(1), 71–77. <https://doi.org/10.2214/ajr.167.1.8659425>
- Omata, M. *et al.* (2017) ‘Asia–pacific clinical practice guidelines on the management of Hepatocellular Carcinoma: A 2017 update’, *Hepatology International*, 11(4), pp. 317–370. doi:10.1007/s12072-017-9799-9.
- Park JW, Chen M, Colombo M, Roberts LR, Schwartz M, Chen PJ, Kudo M, Johnson P, Wagner S, Orsini LS, Sherman M. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. *Liver Int.* 2015 Sep;35(9):2155-66. doi: 10.1111/liv.12818. Epub 2015 Mar 25. PMID: 25752327; PMCID: PMC4691343.
- Pinter M, Trauner M, Peck-Radosavljevic M, Sieghart W. Cancer and liver cirrhosis: implications on prognosis and management. *ESMO Open.* 2016 Mar 17;1(2):e000042. doi: 10.1136/esmoopen-2016-000042. PMID: 27843598; PMCID: PMC5070280.
- Pitman M. B. (1998). Fine needle aspiration biopsy of the liver. Principal diagnostic challenges. *Clinics in laboratory medicine*, 18(3), 483–vi.
- Pocha, C., Dieperink, E., McMaken, K. A., Knott, A., Thuras, P., & Ho, S. B. (2013). Surveillance for hepatocellular cancer with ultrasonography vs. computed tomography -- a randomised study. *Alimentary pharmacology & therapeutics*, 38(3), 303–312. <https://doi.org/10.1111/apt.12370>
- Raza A, Sood GK. Hepatocellular carcinoma review: current treatment, and evidence-based medicine. *World J Gastroenterol.* 2014 Apr 21;20(15):4115-27. doi: 10.3748/wjg.v20.i15.4115. PMID: 24764650; PMCID: PMC3989948.
- Reinhold, C., Hammers, L., Taylor, C. R., Quedens-Case, C. L., Holland, C. K., & Taylor, K. J. (1995). Characterization of focal hepatic lesions with duplex sonography: findings in 198 patients. *AJR. American journal of roentgenology*, 164(5), 1131–1135. <https://doi.org/10.2214/ajr.164.5.7717219>

- Ripoll C, Groszmann RJ, Garcia-Tsao G, Bosch J, Grace N, Burroughs A, et al. Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. *J Hepatol.* 2009;50(5):923-8.
- Saitta, C., Pollicino, T. and Raimondo, G. (2019) ‘Obesity and liver cancer’, *Annals of Hepatology*, 18(6), pp. 810–815. doi:10.1016/j.aohep.2019.07.004.
- Sherman M, Peltekian KM, Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. *Hepatology.* 1995;22:432–438. [PubMed] [Google Scholar]
- Simon, T. G., King, L. Y., Chong, D. Q., Nguyen, L. H., Ma, Y., VoPham, T., Chan, A. T. (2018). Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma: Results from two prospective cohort studies. *Hepatology*, 67(5), 1797–1806. doi:10.1002/hep.29660
- Sin, D.D. *et al.* (2006) ‘Mortality in COPD: Role of Comorbidities’, *European Respiratory Journal*, 28(6), pp. 1245–1257. doi:10.1183/09031936.00133805.
- Singh, M. K., Das, B. K., Choudhary, S., Gupta, D., & Patil, U. K. (2018). *Diabetes and hepatocellular carcinoma: A pathophysiological link and pharmacological management. Biomedicine & Pharmacotherapy*, 106, 991–1002. doi:10.1016/j.biopha.2018.06.095
- Singh, S., Singh, P. P., Singh, A. G., Murad, M. H., & Sanchez, W. (2013). *Anti-Diabetic Medications and the Risk of Hepatocellular Cancer: A Systematic Review and Meta-Analysis. The American Journal of Gastroenterology*, 108(6), 881–891. doi:10.1038/ajg.2013.5
- Tanaka, S., Kitamura, T., Fujita, M., Nakanishi, K., & Okuda, S. (1990). Color Doppler flow imaging of liver tumors. *AJR. American journal of roentgenology*, 154(3), 509–514. <https://doi.org/10.2214/ajr.154.3.2154912>
- Trevisani F, D’Intino PE, Morselli-Labate AM, et al. Serum α -fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. *J Hepatol.* 2001;34(4):570–575. [PubMed] [Google Scholar]

- Van den Borst B, Gosker HR, Schols AM. Central fat and peripheral muscle: partners in crime in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2013; 187: 8–13
- West, J., Card, T. R., Aithal, G. P., & Fleming, K. M. (2017). Risk of hepatocellular carcinoma among individuals with different aetiologies of cirrhosis: a population-based cohort study. *Alimentary pharmacology & therapeutics*, 45(7), 983–990. <https://doi.org/10.1111/apt.13961>
- Wong, R. J., Chou, C., Bonham, C. A., Concepcion, W., Esquivel, C. O., & Ahmed, A. (2014). Improved survival outcomes in patients with non-alcoholic steatohepatitis and alcoholic liver disease following liver transplantation: an analysis of 2002-2012 United Network for Organ Sharing data. *Clinical transplantation*, 28(6), 713–721. <https://doi.org/10.1111/ctr.12364>
- World Health Organization 2020, Globocan Asia Fact Sheet 2020, Viewed at 24 March 2023.
- World Health Organization 2020, Globocan Indonesian Fact Sheet 2020, Viewed at 24 March 2023.
- World Health Organization 2020, Globocan World Fact Sheet 2020, Viewed at 24 March 2023.
- Xia, F. *et al.* (2022) ‘Ruptured hepatocellular carcinoma: Current status of research’, *Frontiers in Oncology*, 12. doi:10.3389/fonc.2022.848903.
- Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. 2019 Oct;16(10):589-604. doi: 10.1038/s41575-019-0186-y. Epub 2019 Aug 22. PMID: 31439937; PMCID: PMC6813818.
- Yang JD, Mohamed HA, Cvinar JL, Gores GJ, Roberts LR, Kim WR. Diabetes Mellitus Heightens the Risk of Hepatocellular Carcinoma Except in Patients With Hepatitis C Cirrhosis. *Am J Gastroenterol.* 2016 Nov;111(11):1573-1580. doi: 10.1038/ajg.2016.330. Epub 2016 Aug 16. Erratum in: *Am J Gastroenterol.* 2017 Feb;112(2):402. PMID: 27527741; PMCID: PMC6040826.
- Yeh, H., Chiang, C.-C. and Yen, T.-H. (2021) ‘Hepatocellular carcinoma in patients with renal dysfunction: Pathophysiology, prognosis, and treatment challenges’, *World Journal of Gastroenterology*, pp . 4104–4142. Doi: 10.3748/wjg.v27.i26.4104.

- Yen, Y. H., Kee, K. M., Li, W. F., Liu, Y. W., Wang, C. C., Hu, T. H., Tsai, M. C., Kuo, Y. H., & Lin, C. Y. (2023). Causes of Death among Patients with Hepatocellular Carcinoma According to Chronic Liver Disease Etiology. *Cancers*, *15*(6), 1687. <https://doi.org/10.3390/cancers15061687>
- Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016). Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. *Hepatology (Baltimore, Md.)*, *64*(1), 73–84. <https://doi.org/10.1002/hep.28431>
- Younossi, Z. M., Otgonsuren, M., Henry, L., Venkatesan, C., Mishra, A., Erario, M., & Hunt, S. (2015). Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. *Hepatology (Baltimore, Md.)*, *62*(6), 1723–1730. <https://doi.org/10.1002/hep.28123>
- Zhang, B. H., Yang, B. H., & Tang, Z. Y. (2004). Randomized controlled trial of screening for hepatocellular carcinoma. *Journal of cancer research and clinical oncology*, *130*(7), 417–422. <https://doi.org/10.1007/s00432-004-0552-0>
- Zhang, Haili MMeda; Li, Hongyu MD; Lan, Xiang MD; Liu, Fei MD; Li, Bo MD; Wei, Yonggang MD,*. Diabetes mellitus affects long-term survival in hepatitis B virus-related hepatocellular carcinoma patients: A propensity score-matched analysis. *Medicine* 100(4):p e24354, January 29, 2021. | DOI: 10.1097/MD.00000000000024354
- Zuckerman, A.J., 1995. IARC monographs on the evaluation of carcinogenic risks to humans. *Journal of Clinical Pathology*, *48*(7), p.691.